9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While generally well tolerated, an increased risk of HHF was found with saxagliptin, which is re fl ected in its label, and there have been rare reports of arthralgia and hypersensitivity reactions with the DPP-4i class (16).”
In the citing paper
“Current treatment protocols propose considering weight impact when choosing diabetes treatment strategies, and GLP-1RAs have shown a notably positive therapeutic profile for overweight or obese individuals with T2DM. 78”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [78]
In the citing paper
“Currently, these guidelines recommend SGLT2is and GLP-1RAs as the preferred therapy among individuals with type 2 diabetes and comorbid ASCVD or HF, and SGLT2is among those with comorbid CKD [8, 9].”
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [147]
In the citing paper
“Based on evidence from large cardiovascular outcomes trials, the latest professional society guidelines continue to recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).1,2”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (45).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“The ADA/EASD consensus report “Management of Hyperglycemia in Type 2 Diabetes, 2018” and the 2019 update (43,44) recommend a patient-centered approach to choosing appropriate pharmacologic treatment of blood glucose.”
BackgroundRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Research works printed but not linked: 2
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Vaz, 2018, Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis, Arch Endocrinol Metab, 62, 337
Cited by
Items 601–700 of 1,000
IDegLira for type 2 diabetes: a systematic review and meta-analysis
Liu, Y., Li, X., Zheng, Y., Wang, X., & Wang, X. (2023) · Endocrine · doi:10.1007/s12020-023-03543-z · Cited by 10
“The ADA “ Standards of Medical Care in Diabetes-2022 ” advise the addition of either insulin (basal or premixed) or a glucagon-like peptide-1 receptor agonist (GLP-1RA) when glycaemic control is not achieved with oral antidiabetic drug [4].”
Tsai, H., Lin, Y., Yeh, J., Huang, Y., Liu, P. P., Peng, C. C., Hsu, J., Lee, Y., Loh, C., Lin, S., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3739 · Cited by 10
Janić, M., Jovanović, M., Janež, A., & Lunder, M. (2023) · Journal of International Medical Research · doi:10.1177/03000605231211402 · Cited by 10
“6 Oral semaglutide has been shown to be effective in reducing glycaemia, that is, glycosylated haemoglobin (HbA1c) and body mass, in the series of Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) studies.”
BackgroundInfluentialFadini, G. P., Buzzetti, R., Pitocco, D., Tortato, E., Scatena, A., Lamacchia, O., Lastoria, G., Simoni, L., Consoli, A., & REX study group (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15486 · Cited by 12
Chinese Guidelines for Medical Nutrition Therapy for Patients with Diabetes (2022 Edition).
(2024) · PubMed Central · doi:10.6133/apjcn.202406_33(2).0001 · Cited by 15
Recomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 13
Lin, M.-H., Yang, H., Yen, C., Wu, C., Jenq, C., Kuo, G. C., Peng, W.-S., Liu, J., Tian, Y.-C., Yang, C.-W., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113578 · Cited by 11
Mody, R., Yu, M. B., Grabner, M., Boye, K. S., Teng, C., & Kwan, A. Y. M. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.09.011 · Cited by 10
Lee, K. A., Jin, H. Y., Kim, Y. J., Kim, S. S., Cho, E.-H., & Park, T. S. (2022) · Medicine · doi:10.1097/md.0000000000028823 · Cited by 9
Females with Diabetes Mellitus Increased the Incidence of Premenstrual Syndrome
Huang, Y.-M., Chien, W., Cheng, C.-G., Cheng, C.-G., Chang, Y.-H., & Chung, C. (2022) · Life · doi:10.3390/life12060777 · Cited by 10
“Sulfonylurea and meglitinide promoted insulin secretion [44] and carried a PMS risk.”
BackgroundInfluentialEvidências cientificas sobre o uso de tirzepatida como tratamento da obesidade
Guimarães, B. C. D. S., Zanoteli, H. C., Chaves, R. P., Marcos, C. R. S. A., Aquino, M. E. F. V. D., Rosseto, J. S., Lopes, R. L., Lampert, A. R., & Peroba, G. G. P. D. A. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n4-137 · Cited by 15
Bletsa, E., Paschou, S. Α., Tsigkou, V., Stampouloglou, P. K., Vasileiou, V., Kassi, G., Oikonomou, E. K., & Siasos, G. (2022) · HORMONES · doi:10.1007/s42000-022-00403-9 · Cited by 9
Dzięgielewska-Gęsiak, S., Fatyga, E., Piłot, M., Wierzgoń, A., & Muc‐Wierzgoń, M. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s377856 · Cited by 10
Schnaars, Y., Gaikwad, S., Gottwald‐Hostalek, U., Uhl, W., Ribot, O., Varanasi, K. V., Rodríguez, L., Torrejón, J., & Gómez, L. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01349-2 · Cited by 12
Khadanga, S., Barrett, K. V., Sheahan, K. H., & Savage, P. D. (2022) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000761 · Cited by 11
Wancewicz, B., Zhu, Y., Fenske, R. J., Weeks, A. M., Wenger, K., Pabich, S., Daniels, M., Punt, M., Nall, R., Peter, D. C., et al. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001493 · Cited by 10
Ogunsanmi, D., Harrison, A., Pakker, A. R., Kovesdy, C. P., Bailey, J. E., & Surbhi, S. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.6.699 · Cited by 10
Kosmalski, M., Różycka-Kosmalska, M., Witusik, A., & Pietras, T. (2020) · Advances in respiratory medicine · doi:10.5603/arm.a2020.0168 · Cited by 9
Bonora, E., Cataudella, S., Marchesini, G., Miccoli, R., Vaccaro, O., Fadini, G. P., Martini, N., & Rossi, E. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.06.006 · Cited by 10
Bodoarca, R., Yeung, R. O., & Lau, D. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2022.04.004 · Cited by 9
Chen, C., Ko, Y., Chen, C.-H., Hung, Y.-J., Wei, T.-E., Chang, T.-H., Ke, S.-S., Kuo, K. N., & Chen, C. (2020) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2022.01.026 · Cited by 9
Flory, J., Guelce, D., Goytia, C. N., Li, J., Min, J. Y., Mushlin, A. I., Orloff, J. N., & Mayer, V. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07838-1 · Cited by 9
Utsunomiya, K., Senda, M., Kakiuchi, S., Kameda, H., Tamura, M., Kurihara, Y., Gunji, R., Fujii, S., & Kaku, K. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13097 · Cited by 9
Reyes‐García, R., Moreno-Pérez, Ó., Bellido, V., Botana-López, M. A., Rodríguez-Hervada, A. D., Fernández‐García, D., Fernández‐García, J. C., Gargallo-Fernández, M., González-Clemente, J. M., Jódar-Gimeno, E., et al. (2023) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2023.03.002 · Cited by 10
Cheung, J. T. K., Yang, A., Wu, H., Lau, E. S. H., Kong, A. P. S., Ronald, C. W., Luk, A. O. Y., Chan, J. C. N., & Chow, E. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3711 · Cited by 10
“38 The American Association of Clinical Endocrinologists (ACE) and American College of Endocrinology (ACE) also recommended combination therapy of metformin plus another agent in addition to lifestyle therapy if HbA1c > 7.5%, regardless of diabetes duration.”
BackgroundInfluentialAhmed, A., Elsadek, H. M., Shalaby, S. M., & El-Nahas, H. M. (2023) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.389949 · Cited by 9
“However, monotherapy is useful for controlling blood glucose for only a few years; then, the patient must use a combination therapy (4).”
BackgroundGiving Prizes (reward) and Its Influence on Student Learning Motivation
Faysal, M., Tabroni, I., Jie, L., Jixiong, C., Nitin, M., & Bradford, S. (2023) · Journal Emerging Technologies in Education · doi:10.55849/jete.v1i2.464 · Cited by 8
Venkatesh, K. K., MacPherson, C., Clifton, R. G., Powe, C. E., Bartholomew, A. B. C., Gregory, D., Trinh, A., McAlearney, A. S., Fiechtner, L. G., Catalano, P. M., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-091176 · Cited by 9
Kaushik, A., Rekhi, T. K., Puri, S., & Tandon, N. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_104_24 · Cited by 9
Willis, H. J., Henderson, M. S. G., Zibley, L. J., & JaKa, M. M. (2025) · JMIR Diabetes · doi:10.2196/67636 · Cited by 8
Ishii, H., Suzuki, S., Williams, P. R., Demiya, S., Aranishi, T., & Treuer, T. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108076 · Cited by 8
Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome
FITCHETT, D. H., Leiter, L. A., Lin, P., Pickering, J., Welsh, R. C., Stone, J. A., Grégoire, J. C., McFarlane, P. A., Langer, A., Gupta, A. K., et al. (2020) · CJC Open · doi:10.1016/j.cjco.2020.04.002 · Cited by 8
Quantifying the Risk Continuum for Cardiovascular Death in Adults with Type 2 Diabetes
Williams, B. A., Blankenship, J. C., Voyce, S. J., Cordova, J. M., Gandhi, P., & Shetty, S. S. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.01.009 · Cited by 8
Sada, K., Hidaka, S., Kashima, J., Morita, M., Sada, K., & Shibata, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13795 · Cited by 8
Li, H., Yang, A., Zhao, S., Chow, E., Javanbakht, M., Li, Y., Lin, D., Xu, L., Zang, D., Wang, K., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15080953 · Cited by 8
“In the latest international guideline, combination insulin therapy with GLP-1 RA is also recommended for a greater efficacy and durability of the treatment effect [2].”
BackgroundAkbarpour, M., Devineni, D., Gong, Y., & Wong, N. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041668 · Cited by 10
“High-intensity statins are recommended for those with DM and ASCVD [23,24], with further non-statin therapy indicated for further LDL-C lowering.”
Miyoshi, H., Matsuhisa, M., Yabe, D., Takahashi, Y., Morimoto, Y., & Terauchi, Y. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01373-w · Cited by 8
Chan, S. P., Lim, L., Chan, J. C. N., & Matthews, D. R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01386-5 · Cited by 10
Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease
Lin, W.-R., Liu, K., Ling, T., Wang, M., & Lin, W. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i4.352 · Cited by 9
Zheng, M., Bernardo, C., Stocks, N. P., Hu, P., & González‐Chica, D. A. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069875 · Cited by 9
Vargas‐Uricoechea, H., Frías, J. P., & Vargas-Sierra, H. D. (2023) · The Review of Diabetic Studies · doi:10.1900/rds.2023.19.14 · Cited by 10
Reclassification of type 2 diabetes to type 1 diabetes in Asturias (Spain) between 2011 and 2020
Escobedo, R. R., Lambert, C., Morales-Sánchez, P., Delgado, E., & Torre, E. L. M. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01069-y · Cited by 9
Cobo, A. L., Masson, W. M., Lobo, M., Barbagelata, L., Forte, E. H., Corral, P., & Nogueira, J. P. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101940 · Cited by 8
Kuoni, S., Müller, D., Simões‐Wüst, A. P., & Steiner, R. (2023) · Journal of Chromatography B · doi:10.1016/j.jchromb.2023.123841 · Cited by 8
Wang, W., Yan, X., Cheng, Z., Zhang, Q., Wang, R., Deng, Y., Ma, J., & Zhu, D. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15263 · Cited by 8
“16 In particular, the combination of a once-weekly GLP-1RA with basal insulin permits a lower number of injections compared with a once-daily GLP-1RA.”
BackgroundJoo, S., Chun, H., Lee, J., Seo, S., Lee, J., & Leem, J. (2023) · Medicina · doi:10.3390/medicina59111919 · Cited by 9
“Increasing the dose or administering combination therapy is common when monotherapy fails to achieve the desired effects [7].”
BackgroundInfluentialBarkas, F., Rizos, C. V., Liamis, G. L., Skoumas, I., Garoufi, A., Rallidis, L. S., Kolovou, G. D., Τζιόμαλος, Κ., Skalidis, E. I., Sfikas, G., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.005 · Cited by 9
Tatulashvili, S., Dreves, B., Meyer, L., Cosson, E., & Joubert, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111592 · Cited by 8
Asgharpour, A., Dinani, A. M., & Friedman, S. L. (2021) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2020.01.04 · Cited by 10
Aggarwal, R., Lu, K., Chiu, N., Bakris, G. L., & Bhatt, D. L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.616 · Cited by 8
Efficacy and Safety of Naproxen for Acute Pain
Weisman, S. R. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0064 · Cited by 10
Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
Rhee, E. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.304 · Cited by 12
Remodeling Type 2 Diabetes Diagnosis: What Individuals Need for Success
Boakye, M. D. S., Miyamoto, S., Greenwood, D. A., Haitsma, K. S. V., Boltz, M. P., & Kraschnewski, J. L. (2022) · Clinical Diabetes · doi:10.2337/cd22-0075 · Cited by 8
Gamayanti, K. A. V., Ratnasari, N. L. M. N., & Bhargah, A. (2018) · Intisari Sains Medis · doi:10.15562/ism.v9i3.306 · Cited by 8
Lam, W. M. J., Khalifah, R. A. A., Flórez, I. D., Cruz‐Lopes, L., Sekercioglu, M. F., Couban, R., Fu, R., Cherney, D. Z. I., & Sekercioglu, N. (2020) · Diabetic Medicine · doi:10.1111/dme.14231 · Cited by 8
Combined Albuminuria and Estimated GFR Laboratory Reporting Affects Primary Care Management of CKD
Vassalotti, J. A., & Thavarajah, S. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.04.005 · Cited by 10
Wang, Y., Wu, H., Yang, J., Ma, J., Li, H., He, X., Xiao, Y., & Pan, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1486655 · Cited by 7
Alogliptin and Heart Failure Outcomes in Patients With Type 2 Diabetes
Layman, S. N., Elliott, W. V., Neu, D. W., Howard, T. G., & Hamby, A. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221135656 · Cited by 7
“Additionally in the setting of diabetes, potentiation of SDF-1 may lead to cardiac fi brosis, increasing the risk of developing HF. 14,15 While this proposed mechanism has not been proven, it may help to explain both our fi ndings that alogliptin appears to have a greater effect on risk of exacerbation in pre-existing H…”
BackgroundInfluentialNilsson, K., Andersson, E., Persson, S., Karlsdotter, K., Skogsberg, J., Gustavsson, S., JENDLE, J. H., & Carlsson, K. S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14921 · Cited by 7
“glucagon-like peptide-1 receptor agonist (GLP-1 RA) or sodiumglucose cotransporter-2 (SGLT-2) inhibitors for people with T2D and established cardiovascular disease (eCVD).(7,8) SGLT-2 inhibitors lower blood glucose levels by increasing glucose excretion in the urine and were first approved for the treatment of T2D.”
BackgroundYokoyama, H., Araki, S., Kawai, K., Yamazaki, K., Tomonaga, O., Maeda, H., Ohtaki, M., Obata, H., Sone, H., Kabata, D., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110674 · Cited by 9
Díaz-Rojas, M., González‐Andrade, M., Aguayo‐Ortiz, R., Rodríguez‐Sotres, R., Pérez‐Vásquez, A., Madariaga‐Mazón, A., & Mata, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1281045 · Cited by 7
Wong, H. J., Lin, N., Teo, Y. N., Syn, N. L. X., Teo, Y. H., & Sia, C. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00640-w · Cited by 8
“…of research has demonstrated the potential of some T2DM drugs to reduce adverse outcomes in patients with concomitant CVD. Metformin is the most widely prescribed medication for T2DM management [3] and is the first-line drug recommended by major guidelines since its introduction in 1957 [4, 5].”
Recent and Upcoming Therapies for Management of Type 2 Diabetes: A Review
Gokalani, R. A., Saiyed, M., Dey, A. K., & Sheikh, F. (2024) · Preventive Medicine Research & Reviews · doi:10.4103/pmrr.pmrr_12_24 · Cited by 8
Di, X., Chi, Y., & Wei, X. (2024) · Food & Nutrition Research · doi:10.29219/fnr.v68.10828 · Cited by 7
“Diabetes was diagnosed based on the blood glucose tests conducted by doctors (13, 14).”
MethodPark, C. S., Choi, J., Kwak, S., Lee, S., Kim, H., Kim, Y.-J., Kwak, S. H., & Park, J. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004244 · Cited by 8
Bergenstal, R. M., Ásbjörnsdóttir, B., Bari, T. J., Hulkund, S., Winhofer, Y., & Wysham, C. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0050 · Cited by 11
Aravind, S. R., Singh, K. P., Aquitania, G. P., Mogylnytska, L., Zalevskaya, A. G., Matyjaszek‐Matuszek, B., Wernicke‐Panten, K., Nguyên‐Pascal, M., Pierre, S., Rotthaeuser, B., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01255-7 · Cited by 7
McRae, M., & Wang, C. C. L. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.11.012 · Cited by 8
Nikitin, D., Lin, G. A., Campbell, J. D., Hansen, R. N., Brouwer, E., Chen, Y., Herron-Smith, S., Agboola, F. O., & Pearson, S. D. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.6.680 · Cited by 9
GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2030034 · Cited by 7
Trends in add-on medications following metformin monotherapy for type 2 diabetes
Swart, E. C. S., Neilson, L. M., Munshi, K. D., Peasah, S. K., Henderson, R. R., & Good, C. B. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.11.1253 · Cited by 7
Tramunt, B., Disse, E., Chevalier, N., Bordier, L., Cazals, L., Dupuy, O., Marre, M., Matar, O., Meyer, L., Noilhan, C., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01327-8 · Cited by 7
Strandberg, R. B., Nilsen, R. M., Pouwer, F., Igland, J., Forster, R. B., Jenum, A. K., Buhl, E. S., & Iversen, M. M. (2022) · Patient Education and Counseling · doi:10.1016/j.pec.2022.107577 · Cited by 7
Analysis of oral hypoglycemic drugs that are subject to reimbursement in Ukraine
Власенко, І. О. (2022) · Farmatsevtychnyi zhurnal · doi:10.32352/0367-3057.5.22.04 · Cited by 7
Lu, J., Ou, H., Wu, C., Yang, C.-Y., Jiang, J., Lu, C., Jiang, Y., Chang, T., Chang, Y., Hsieh, M.-L., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-29791-7 · Cited by 7
Gentile, S., Satta, E., Guarino, G., & Strollo, F. (2023) · Diabetology · doi:10.3390/diabetology4010013 · Cited by 7
Yen, F., Chang, S., Wei, J. C., Shih, Y., & Hwu, C. (2023) · Pharmaceuticals · doi:10.3390/ph16050643 · Cited by 7
Wang, D., He, S., Zhong, G., Meng, J., Bi, Q., & Tu, R. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/162578 · Cited by 7
Metformin in Type 2 Diabetes: Evidence for its Beneficial Effects on Frailty and Sarcopenia
Pyrgioti, E. E., Karakousis, N. D., Georgakopoulos, P. N., & Παπάνας, Ν. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230727101141 · Cited by 7
Bermudez, S. R., Anderson, J. R., Bos, A. J., & Ray, G. M. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad177 · Cited by 8
Shabnam, S., Gillies, C., Davies, M. J., DEX, T. A., Melson, E., Khunti, K., Webb, D. R., Zaccardi, F., & Seidu, S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110888 · Cited by 7
Monda, V. M., Voci, C., Strollo, F., Passaro, A., Greco, S., Monesi, M., Bigoni, R., Porcellati, F., Piani, D., Satta, E., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01472-8 · Cited by 7
“…reduced COVID-19 mortality in T2DM [27]; however, their lower hypoglycemic potential and typical utilization in people with less severe T2DM forms [28] could have resulted in the selection of clusters of patients with less severe diabetes and related complications, thus introducing a bias into…”
BackgroundZhao, J., Hussain, S. A., & Maddu, N. (2024) · Acta Cirúrgica Brasileira · doi:10.1590/acb390124 · Cited by 7
Li, J., Huang, Y., Yang, X., Cai, Y., Wang, Y., Dai, W., Jiang, L., Wang, C., & Wen, Z. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101927 · Cited by 7
“The importance of maintaining normal hepatic gluconeogenic rates in the management of T2DM has been underscored by current therapeutical approaches to suppression of gluconeogenesis including intermediate-acting insulin given at bedtime and metformin [4].”
BackgroundMalik, F. S., Liese, A. D., Ellyson, A. M., Reid, L. A., Reboussin, B. A., Sauder, K. A., Frongillo, E. A., Pihoker, C., Dabelea, D., Reynolds, K., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111608 · Cited by 8
Rikin, S., Bauman, L. J., Arnaoudova, I., Palo, K. E. D., Suda, N., Gupta, S., Deng, Y., & Golestaneh, L. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004155 · Cited by 8
Otsuka, E., Kitamura, M., Funakoshi, S., Mukae, H., & Nishino, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1362242 · Cited by 8
“The current guidelines for managing type 2 diabetes recommend GLP-1 RAs as fi rst-line injectable therapy even before insulin initiation (American Diabetes Association Professional Practice Committee, 2022).”
BackgroundJu, M., Deng, T., Jia, X., Gong, M., Li, Y., Liu, F., & Yin, Y. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01359-z · Cited by 7
“We selected the major antidiabetic drugs, including metformin, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, insulin and its analogs, thiazolidinediones, sulfonylureas, and alpha-glucosidase inhibitors [28, 29].”
BackgroundAn, J., Sim, J. J., Zhou, M. M., Zhou, H., Choi, S. K., Brettler, J. W., Ong‐Su, A. L., & Reynolds, K. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14915 · Cited by 7
Designing and Evaluating an Ensemble Reasoning-based Clinical Decision Support System
Rashid, S. M., & McGuinness, D. L. (2025) · Data Intelligence · doi:10.3724/2096-7004.di.2025.0001 · Cited by 7
Al‐Sofiani, M. E., Batais, M. A., Aldhafiri, E., & Alzaid, A. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.04.003 · Cited by 8
Screening for Autoantibodies in Type 1 Diabetes: A Call to Action
Петерс (2021) · The Journal of Family Practice · doi:10.12788/jfp.0223 · Cited by 11
Primary Prevention of CVD with Aspirin: Benefits vs Risks
Weisman (2021) · The Journal of Family Practice · doi:10.12788/jfp.0222 · Cited by 9
Newer antidiabetic agents: at what price will they be cost effective?
Ranjit Unnikrishnan, I., & Mohan, V. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00264-3 · Cited by 7
Clinical Efficacy of Imeglimin (Twymeeg) for Elderly Patient with Type 2 Diabetes Mellitus (T2DM)
OKADA, M., Bando, H., Iwatsuki, N., Ogawa, T., & Sakamoto, K. (2022) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2022/asjbccr.6259 · Cited by 7
Orsi, E., Solini, A., Bonora, E., Vitale, M., Garofolo, M., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F. L., Laviola, L., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01942-8 · Cited by 7
Elaidy, S. M., Tawfik, M. M., Ameen, A. M., Hassan, W. A., Sherif, I. E., Amin, M. K., & Elkholy, S. E. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120904 · Cited by 7
ALTUN, H. K., & Suna, G. (2022) · Cureus · doi:10.7759/cureus.30750 · Cited by 11
“The classification of glucose-lowering agents that effects weight change has been made according to the American Diabetes Association's Standards of Medical Care in Diabetes-2022 [14].”
MethodRodríguez‐Ramírez, A. M., Alcántara-Garcés, M. T., Hernández-Jiménez, S. C., García-Ulloa, A. C., Arcila-Martínez, D., Velázquez-Jurado, H., & Arizmendi-Rodríguez, R. E. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s392672 · Cited by 9
Moke, E. G., Omogbai, E. K. I., Osagie-Eweka, S. E., Uchendu, A. P., Obayuwana, M. O., Okoro-Akpandu, E., & Ben‐Azu, B. (2023) · Laboratory Animal Research · doi:10.1186/s42826-023-00159-2 · Cited by 10
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S125-S143
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200161106
- Cited by
- 1,555
- References
- 106
- Citations by year
- 2026: 42 · 2025: 132 · 2024: 219 · 2023: 393 · 2022: 403 · 2021: 153
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.